Literature DB >> 20401503

Osteonecrosis of the jaw related to sunitinib.

Felix P Koch1, Christian Walter, Torsten Hansen, Elke Jäger, Wilfried Wagner.   

Abstract

CASE REPORT: A 59-year-old male patient was referred to the hospital with exposed bone measuring 10 mm in diameter in the posterior, left-side region of the lower jaw. Two months previous, the first molar had been extracted. The patient had contracted renal cell carcinoma and had been treated by nephrectomy in 2003. Soft tissue metastases occurred. After initial therapy with interferon and vinblastine, a relapse occurred and the therapy was changed to sorafenib, followed by sunitinib. Osteonecrosis of the lower jaw appeared 1 year after initial and exclusive therapy with sunitinib.
CONCLUSIONS: Bisphosphonates had never been applied. With increasing application of multi-kinase inhibitors, complications due to osteonecrosis could occur more frequently.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20401503     DOI: 10.1007/s10006-010-0224-y

Source DB:  PubMed          Journal:  Oral Maxillofac Surg        ISSN: 1865-1550


  26 in total

1.  New foundations in understanding osteonecrosis of the jaws.

Authors:  Leon A Assael
Journal:  J Oral Maxillofac Surg       Date:  2004-02       Impact factor: 1.895

2.  Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?

Authors:  J Ayllon; V Launay-Vacher; J Medioni; C Cros; J P Spano; S Oudard
Journal:  Ann Oncol       Date:  2009-02-02       Impact factor: 32.976

Review 3.  Role of tyrosine kinase inhibitors in cancer therapy.

Authors:  Amit Arora; Eric M Scholar
Journal:  J Pharmacol Exp Ther       Date:  2005-07-07       Impact factor: 4.030

4.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors:  Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

5.  Actinomycosis of the jaws--histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis.

Authors:  Torsten Hansen; Martin Kunkel; Erik Springer; Christian Walter; Achim Weber; Ekkehard Siegel; C James Kirkpatrick
Journal:  Virchows Arch       Date:  2007-10-20       Impact factor: 4.064

Review 6.  The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.

Authors:  Jeanine M Roodhart; Marlies H Langenberg; Els Witteveen; Emile E Voest
Journal:  Curr Clin Pharmacol       Date:  2008-05

7.  Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

Authors:  C Kollmannsberger; D Soulieres; R Wong; A Scalera; R Gaspo; G Bjarnason
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

8.  Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

Authors:  Christian Walter; Bilal Al-Nawas; Knut A Grötz; Christian Thomas; Joachim W Thüroff; Viktoria Zinser; Heinold Gamm; Joachim Beck; Wilfried Wagner
Journal:  Eur Urol       Date:  2008-06-26       Impact factor: 20.096

Review 9.  Flt3 receptor tyrosine kinase as a drug target in leukemia.

Authors:  Dirk Schmidt-Arras; Joachim Schwäble; Frank-D Böhmer; Hubert Serve
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

10.  Osteonecrosis of the jaw, a recently recognized sequela of bisphosphonate therapy: case report.

Authors:  Corey J Langer
Journal:  Support Cancer Ther       Date:  2006-01-01
View more
  28 in total

Review 1.  Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity.

Authors:  Valesca Sander Koth; Maria Antonia Figueiredo; Fernanda Gonçalves Salum; Karen Cherubini
Journal:  Dentomaxillofac Radiol       Date:  2016-05-31       Impact factor: 2.419

Review 2.  Osteochemonecrosis: an overview.

Authors:  John Hellstein
Journal:  Head Neck Pathol       Date:  2014-11-20

3.  Osteonecrosis of the jaw associated with ziv-aflibercept.

Authors:  Hani Mawardi; Peter Enzinger; Nadine McCleary; Reshma Manon; Alessandro Villa; Nathaniel Treister; Sook-Bin Woo
Journal:  J Gastrointest Oncol       Date:  2016-12

4.  Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro.

Authors:  A M Pabst; M Krüger; T Ziebart; C Jacobs; C Walter
Journal:  Clin Oral Investig       Date:  2015-01-16       Impact factor: 3.573

Review 5.  Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.

Authors:  Christine B Boers-Doets; Joel B Epstein; Judith E Raber-Durlacher; Jan Ouwerkerk; Richard M Logan; Jan A Brakenhoff; Mario E Lacouture; Hans Gelderblom
Journal:  Oncologist       Date:  2011-12-29

6.  Does CBCT alter the diagnostic thinking efficacy, management and prognosis of patients with suspected Stage 0 medication-related osteonecrosis of the jaws?

Authors:  Hiroaki Shimamoto; Tristan R Grogan; Tomomi Tsujimoto; Naoya Kakimoto; Shumei Murakami; David Elashoff; Tara L Aghaloo; Sotirios Tetradis
Journal:  Dentomaxillofac Radiol       Date:  2017-12-15       Impact factor: 2.419

Review 7.  [Progress on medication-related osteonecrosis of the jaw].

Authors:  Qi-Zhang Wang; Ji-Yuan Liu; Jian Pan
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2018-10-01

Review 8.  Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.

Authors:  J Chang; A E Hakam; L K McCauley
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

9.  Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Authors:  Ourania Nicolatou-Galitis; Maria Kouri; Erofili Papadopoulou; Emmanouil Vardas; Dimitra Galiti; Joel B Epstein; Sharon Elad; Giuseppina Campisi; Nikolaos Tsoukalas; Kivanc Bektas-Kayhan; Winston Tan; Jean-Jacques Body; Cesar Migliorati; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2018-10-23       Impact factor: 3.603

10.  Osteonecrosis of the Jaw in the Absence of Antiresorptive or Antiangiogenic Exposure: A Series of 6 Cases.

Authors:  Tara L Aghaloo; Sotirios Tetradis
Journal:  J Oral Maxillofac Surg       Date:  2016-07-30       Impact factor: 1.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.